LUIS CARREÑO PÉREZ-rekin lankidetzan egindako argitalpenak (7)

2010

  1. Interleucinas en la fisiopatología de la artritis reumatoide: más allá de las citocinas proinflamatorias

    Reumatologia Clinica, Vol. 6, Núm. SUPPL. 3

2009

  1. Association between anti-cyclic citrullinated peptide antibodies and ischemic heart disease in patients with rheumatoid arthritis

    Arthritis Care and Research, Vol. 61, Núm. 4, pp. 419-424

  2. The value of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis: Do they imply new risk factors?

    Drug News and Perspectives, Vol. 22, Núm. 9, pp. 543-548

2008

  1. Combined therapy with rituximab plus cyclophosphamide/vincristine/ prednisone for Sjogren's syndrome-associated B-cell non-Hodgkin's lymphoma

    Clinical Reviews in Allergy and Immunology, Vol. 34, Núm. 1, pp. 80-84

2006

  1. Association of anti-cyclic citrullinated peptide and anti-Sa/citrullinated vimentin autoantibodies in rheumatoid arthritis

    Arthritis Care and Research, Vol. 55, Núm. 4, pp. 657-661

  2. Efficacy and safety of Etanercept, high-dose intravenous gammaglobulin and plasmapheresis combined therapy for lupus diffuse proliferative nephritis complicating pregnancy

    Lupus, Vol. 15, Núm. 12, pp. 881-885

2005

  1. Prevalence of IgG anti-α-fodrin antibodies in Sjögren's syndrome

    Annals of the New York Academy of Sciences